Related Experiment Video
Updated: Jan 9, 2026
Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery
Published on: August 16, 2019
Plasma expression of lncRNA Wisper in patients with heart failure and patients with myocardial infarction
Jordanka G Doneva1,2, Veselin D Valkov1,3, Ivan S Donev4
1Department of Propedeutics of Internal Medicine, Medical University of Varna, Varna, Bulgaria.
Insights
Elevated plasma Wisper long noncoding RNA (lncRNA) levels were found in patients with heart failure (HF) and ST-elevation myocardial infarction (STEMI). This suggests Wisper may serve as a biomarker for cardiac fibrosis in these conditions.
Area of Science:
- Cardiology
- Molecular Biology
- Biomarker Discovery
Background:
- Heart failure (HF) and ST-elevation myocardial infarction (STEMI) are leading causes of mortality.
- Cardiac fibrosis is a common pathological feature in HF and STEMI.
- Long noncoding RNAs (lncRNAs) are implicated in the development of cardiac fibrosis.
Purpose of the Study:
- To investigate the plasma expression levels of the lncRNA Wisper in patients with HF and STEMI.
- To evaluate the diagnostic accuracy of Wisper as a biomarker for HF and STEMI.
- To explore the correlation between Wisper expression and clinical parameters.
Main Methods:
- Retrospective analysis of plasma samples from 28 HF patients, 37 STEMI patients, and 15 healthy controls.
- Quantification of lncRNA Wisper expression using RT-qPCR.
- Diagnostic accuracy assessed via receiver operating characteristic (ROC) curve analysis.
Main Results:
- Plasma Wisper expression was significantly elevated in both HF and STEMI patients compared to controls.
- No significant difference in Wisper levels was observed between HF and STEMI groups.
- ROC analysis indicated good discriminatory power of Wisper for identifying HF and STEMI patients.
Conclusions:
- Elevated plasma Wisper levels are associated with HF and STEMI.
- Wisper shows potential as a circulating biomarker for cardiac fibrosis in these conditions.
- Further research is warranted to elucidate the precise role of Wisper in cardiac pathophysiology.
Background:
Heart failure (HF) and ST-elevation myocardial infarction (STEMI) are the major causes of morbidity and mortality worldwide. Recent evidence indicates that long noncoding RNAs (lncRNAs) participate in cardiac fibrosis, which develops to varying degrees in these conditions.
Patients And Methods:
This retrospective study analyzed the plasma expression levels of lncRNA Wisper using RT-qPCR in 28 patients with HF (NYHA class III - IV, reduced ejection fraction), 37 patients with STEMI, and 15 healthy controls. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis, and correlations with clinical parameters were evaluated.
Results And Conclusions:
Patients with HF and STEMI showed significantly higher plasma Wisper expression than that of controls (p = 0.021 and p = 0.03, respectively), with no significant difference between the HF and STEMI groups (p = 1.0). In patients with HF, Wisper expression negatively correlated with age (rho = -0.452, p = 0.016). ROC analysis demonstrated good discriminatory power of Wisper in distinguishing HF (AUC = 0.783, 95% CI: 0.648-0.919, p = 0.002) and STEMI (AUC = 0.780, 95% CI: 0.658-0.903, p = 0.002) from controls. The elevated plasma expression of Wisper in patients with HF and STEMI suggests its potential role as a circulating biomarker of cardiac fibrosis.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Heart Failure III: Clinical Manifestations
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:27Heart Failure I: Introduction